What's a Clinician to Do? Implementation of the 2013 Prevention Guidelines
Dr. Donald Lloyd-Jones, thought leader who played a major role in the development of the 2013 risk assessment and prevention guidelines, takes the learner through a case-based approach in the clinical application of the guidelines.
Credit: .92 (0.5 Pharmacology)
Upon completion, participants will be able to:
- Donald Lloyd-Jones, MD/ScM
- Describe process for assessing appropriateness for statin therapy in the high risk primary prevention patient
- Describe steps in the addition of non-statin therapy to the treatment regimen of a patient with residual risk.